Vigil Neuroscience to Present at Evercore ISI 6th Annual HealthCONx Conference
Vigil Neuroscience Reports Positive Interim Data from Phase 2 IGNITE Proof-of-Concept Clinical Trial Evaluating Iluzanebart (VGL101) as a Treatment for ALSP and from Ongoing Natural History Study ILLUMINATE
Vigil Neuroscience Reports Third Quarter 2023 Financial Results and Provides Business Update
Vigil Neuroscience Announces First Participant Dosed in Phase 1 Clinical Trial in Healthy Volunteers Evaluating VG-3927, a Small Molecule TREM2 Agonist, for Potential Treatment of Alzheimer’s Disease
Vigil Neuroscience to Present at Jefferies Inaugural Biotech CNS/Neuro Summit
Vigil Neuroscience Receives Positive Opinion from European Medicines Agency on Orphan Drug Designation for VGL101 for the Treatment of ALSP
Vigil Neuroscience Presents VGL101 Complete Phase 1 Data and Phase 2 IGNITE Trial Design at the 2023 American Neurological Association Annual Meeting
Vigil Neuroscience Announces Update on its Small Molecule TREM2 Agonist Program
Vigil Neuroscience to Present at 2023 Morgan Stanley Global Healthcare Conference
Vigil Neuroscience Reports Second Quarter 2023 Financial Results and Provides Business Update
Displaying 1 - 10 of 20